| Prev Close | 22.63 |
| Day Low/High | 22.50 / 23.60 |
| 52 Wk Low/High | 6.25 / 23.57 |
Amicus Therapeutics, Inc. (FOLD)
23.23
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 260.59B |
| Market Cap | 5.90B |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Here Are Several Promising Rare Disease Stocks
These small biotech concerns are undervalued.
I'm Unapologetically Overweight in These 2 Sectors
The two are homebuilding and biotech, and there are stocks within those sectors where I've parked my money.
A Pair of Rare Disease Biotech Concerns Worth a Good Look
Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.
A Handful of Small Biotechs That Make for Merger Chatter
The names include a veterinary drug concern plus companies with successful drugs on the market.
2 Small Biotechs With Sagging Shares but Promising Prospects
The stocks of these two developmental concerns have slid recently, but there are reasons to believe they will improve.
Amicus Therapeutics Looks Impressive If it Can Rally Above $18
The combination of three charts gives me a bullish view on FOLD.
2 Small-Cap Stocks That Are Still a Bargain
Despite the January rally, this biotech name and building materials firm still have further to rise.
Three to Watch in Biotech
Other than the Dow, most of major market indices are showing small gains heading into the last hour of trading. The biotech sector has not participated in today's rally and is down some 0.75% on the day so far. I am watching a few small biotech and ...
Here's My Take on Biotech Stocks
I think M&A activity will pick up markedly going forward across the industry.
Markets Struggle to Find Direction
Markets continue to meander between being slightly up or slightly down as equities struggle for a direction after yesterday's big slide. New homes sales for the month of February were above expectations with the average selling price 10% above the s...
2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs
Outside of oncology, the rare disease area is a good target for M&A in 2018.
Circle These Biotech Acquisition Candidates
Outside of oncology, the rare disease area is a good target for M&A in 2018.
Markets Seeing A Narrow Trading Range
Markets have weakened over the past hour. There has been a very narrow trading range so far today. Biotech continued to strengthen. I think the sector is gaining a bit of strength as some small caps like Amicus Therapeutics present at the JP Morgan...
10 Biotech Stocks Investors Should Put on Their Shopping List for 2018
Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.
10 Biotech Stocks to Watch in 2018
There are a variety of players that should be active in the M&A space next year.
Biotech Stocks to Watch: Part 1
Upcoming catalysts will redefine the biotech market -- and here are 3 names that will feel the impact.
Mylan Soars After FDA Approval for Generic Copaxone --Biotech Movers
The pharmaceutical company on Oct. 3 said the FDA has approved its generic version of Teva's multiple sclerosis drug Copaxone.
Remember, Fed News Is a Trigger for the Computers
So I'm staying focused on stock picking.
Strong Action in Individual Stocks Starts to Feel a Bit Frothy
It's hard to predict when momentum will slow, but it could be time to take some profits when the market is as strong as this morning.
The Flippers Are at Work and the Bears Are Hopeful
Apple and its suppliers are dragging the market down.
Time to Bring Amicus Therapeutics Into the 'FOLD'
Shares of this biotech look ready for further strong gains.
REITs Are Strong on M&A News
The market is maintaining slight gains across the board as we approach the noon hour. Lodging REITS are strong today on the back of the news that RLJ Lodging Trust has received a competing buyout offer from a PE firm for $24 a share. Shares are up ...
Trump's FDA: A Friendlier Biotech Sheriff
There still will be winners and losers, but the new administration's FDA is a net plus for the industry.
Keep Biotech Trigger Fingers Holstered
Three names show how fast biotechs can become oversold when the market acts in knee-jerk fashion.
Vegas Baby: Rolling '777s' in Biotech
Three small-cap biotechs with attractive risk/reward profiles.
7 Things to Watch in Biotech Now
M&A, drug approvals and Trump are all on my watch list.
3 Small Biotechs With Insider Buying
Insiders have an edge in this complex sector, so it's worth checking them out.
A Biotech Trio to Like Going Into 2017
Egalet, Portola Pharmaceuticals and Amicus Therapeutics hold promise for improvement.
